세계의 비소세포폐암(NSCLC) 시장 : 기회 및 전략(-2034년)

Non-small cell lung cancer (NSCLC) refers to a group of lung cancers that behave and respond to treatment differently than small cell lung cancer. It includes several histological subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC typically grows and spreads more slowly than small cell lung cancer (SCLC).

The non-small cell lung cancer (NSCLC) market consists of revenues generated by entities that develop and provide therapeutics, diagnostics, and treatment services targeted at NSCLC patients. These services and products are used primarily in hospital settings, cancer specialty centers, outpatient oncology clinics, and sometimes in home care environments.

The global non-small cell lung cancer (NSCLC) market reached a value of nearly $38,199.05 million in 2024, having grown at a compound annual growth rate (CAGR) of 7.68% since 2019. The market is expected to grow from $38,199.05 million in 2024 to $63,708.97 million in 2029 at a rate of 10.77%. The market is then expected to grow at a CAGR of 10.55% from 2029 and reach $105,206.16 million in 2034.

Rising Prevalence Of Smoking And Air Pollution

Rising prevalence of smoking and air pollution propelled the growth of the non-small cell lung cancer (NSCLC) market during the historic period. The increasing prevalence of smoking and air pollution led to a higher incidence of non-small cell lung cancer, which in turn drove demand for effective diagnostics and treatments. For instance, in May 2024, according to American Lung Association, an organization working to save lives by improving lung health and preventing lung disease, the proportion of people smoking fewer than 15 cigarettes a day increased 85% from 32% to 58%. Moreover, in May 2025, according to the United States Environmental Protection Agency, a US-based government agency, in 2023, about 66 million tons of pollutants were emitted into the atmosphere in the United States. Therefore, growing renovation and remodeling activities propelled the growth of the non-small cell lung cancer (NSCLC) market.

Bromodomain Inhibitor Gains Fast Track Designations for Resistant Non-Small Cell Lung Cancer

Companies in the non-small cell lung cancer (NSCLC) market are developing bromodomain inhibitors to block epigenetic readers that drive oncogene expression, thereby halting tumor growth and reversing therapy resistance. For instance, in August 2025, TOLREMO Therapeutics AG, a Switzerland-based biotech company, announces that its lead candidate, TT125-802, receives two Fast Track designations from the United States Food and Drug Administration for the treatment of non-small cell lung cancer with epidermal growth factor receptor mutations and kirsten rat sarcoma viral oncogene homolog G12C mutations after progression on targeted therapies. TT125-802, an oral cyclic AMP response element binding protein binding protein/p300 inhibitor, shows encouraging efficacy and safety in Phase 1 trials, including durable monotherapy responses without thrombocytopenia. These designations support accelerated development of TT125-802 as a differentiated therapy to address drug resistance in non-small cell lung cancer.

The global non-small cell lung cancer (NSCLC) market is highly concentrated, with large players operating in the market. The top 10 competitors in the market made up 76.71% of the total market in 2024.

Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global non-small cell lung cancer (NSCLC) market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for non-small cell lung cancer (NSCLC)? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The non-small cell lung cancer (NSCLC) market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider non-small cell lung cancer (NSCLC) market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics: - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by therapy and distribution channel.
• Key Trends: - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis:- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Global Market Size And Growth: Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis: - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation: - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by therapy and distribution channel and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size And Growth: - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape: - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies:- Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking: - Briefs on the financials comparison between major players in the market.
• Competitive Dashboard: - Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions: - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
• Recent Developments:- Information on recent developments in the market covered in the report.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for non-small cell lung cancer (NSCLC) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups
• Appendix:- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types
• 2) By Therapy: Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy; Other Therapies
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels
• Companies Mentioned: Merck & Co., Inc.; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Pfizer Inc.
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; non-small cell lung cancer (NSCLC) indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Non-Small Cell Lung Cancer (NSCLC) - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Non-Small Cell Lung Cancer (NSCLC) Market Definition And Segmentations
• 6.4 Market Segmentation By Type
  • 6.4.1 Squamous Cell Carcinoma
  • 6.4.2 Large Cell Carcinoma
  • 6.4.3 Adenocarcinoma
  • 6.4.4 Other Types
• 6.5 Market Segmentation By Therapy
  • 6.5.1 Radiation Therapy
  • 6.5.2 Chemotherapy
  • 6.5.3 Targeted therapy
  • 6.5.4 Immunotherapy
  • 6.5.5 Other Therapies
• 6.6 Market Segmentation By Distribution Channel
  • 6.6.1 Hospital Pharmacy
  • 6.6.2 Online Pharmacy
  • 6.6.3 Other Distribution Channels

7 Major Market Trends

• 7.1 Bromodomain Inhibitor Gains Fast Track Designations for Resistant Non-Small Cell Lung Cancer
• 7.2 Dual-Immune Activation Therapy Shows Promise in Immunotherapy-Resistant NSCLC
• 7.3 Rapid 24-Hour Tumor Profiling for Precision NSCLC Treatment
• 7.4 Oral Tyrosine Kinase Inhibitors Accelerate Targeted NSCLC Treatment Advances
• 7.5 FDA Clears Investigational mRNA-Based Precision Immunotherapy
• 7.6 Third-Generation EGFR-TKI Gains Approval for Stage III NSCLC Maintenance Therapy

8 Global Non-Small Cell Lung Cancer (NSCLC) Growth Analysis And Strategic Analysis Framework

• 8.1 Global Non-Small Cell Lung Cancer (NSCLC) PESTEL Analysis
  • 8.1.1 Political
  • 8.1.2 Economic
  • 8.1.3 Social
  • 8.1.4 Technological
  • 8.1.5 Environmental
  • 8.1.6 Legal
• 8.2 Analysis Of End Users (B2B)
  • 8.2.1 Hospitals
  • 8.2.2 Specialty Clinics
  • 8.2.3 Homecare
  • 8.2.4 Research Institutes
  • 8.2.5 Other End Users
• 8.3 Global Non-Small Cell Lung Cancer (NSCLC) Market Growth Rate Analysis
• 8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 8.4.1 Market Drivers 2019 - 2024
  • 8.4.2 Market Restraints 2019- 2024
• 8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
• 8.6 Forecast Growth Contributors/Factors
  • 8.6.1 Quantitative Growth Contributors
  • 8.6.2 Drivers
  • 8.6.3 Restraints
• 8.7 Global Non-Small Cell Lung Cancer (NSCLC) Total Addressable Market (TAM)

9 Global Non-Small Cell Lung Cancer (NSCLC) Market Segmentation

• 9.1 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.2 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.3 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.4 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.5 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Large Cell Carcinoma, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.6 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.7 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Other Types, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Non-Small Cell Lung Cancer (NSCLC) Market, Regional and Country Analysis

• 10.1 Global Non-Small Cell Lung Cancer (NSCLC) Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Global Non-Small Cell Lung Cancer (NSCLC) Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

• 11.1 Summary
• 11.2 Market Overview
  • 11.2.1 Region Information
  • 11.2.2 Market Information
  • 11.2.3 Background Information
  • 11.2.4 Government Initiatives
  • 11.2.5 Regulations
  • 11.2.6 Regulatory Bodies
  • 11.2.7 Major Associations
  • 11.2.8 Taxes Levied
  • 11.2.9 Corporate Tax Structure
  • 11.2.10 Investments
  • 11.2.11 Major Companies
• 11.3 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.4 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.5 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.6 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
• 11.7 China Market
• 11.8 Summary
• 11.9 Market Overview
  • 11.9.1 Country Information
  • 11.9.2 Market Information
  • 11.9.3 Background Information
  • 11.9.4 Government Initiatives
  • 11.9.5 Regulations
  • 11.9.6 Regulatory Bodies
  • 11.9.7 Major Associations
  • 11.9.8 Taxes Levied
  • 11.9.9 Corporate Tax Structure
  • 11.9.10 Investments
  • 11.9.11 Major Companies
• 11.10 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.11 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.12 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.13 India Market
• 11.14 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.15 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.16 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.17 Japan Market
• 11.18 Summary
• 11.19 Market Overview
  • 11.19.1 Country Information
  • 11.19.2 Market Information
  • 11.19.3 Background Information
  • 11.19.4 Government Initiatives
  • 11.19.5 Regulations
  • 11.19.6 Regulatory Bodies
  • 11.19.7 Major Associations
  • 11.19.8 Taxes Levied
  • 11.19.9 Corporate Tax Structure
  • 11.19.10 Investments
  • 11.19.11 Major Companies
• 11.20 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.21 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.22 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.23 South Korea Market
• 11.24 Summary
• 11.25 Market Overview
  • 11.25.1 Country Information
  • 11.25.2 Market Information
  • 11.25.3 Background Information
  • 11.25.4 Government Initiatives
  • 11.25.5 Regulations
  • 11.25.6 Regulatory Bodies
  • 11.25.7 Major Associations
  • 11.25.8 Taxes Levied
  • 11.25.9 Corporate Tax Structure
  • 11.25.10 Investments
  • 11.25.11 Major Companies
• 11.26 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.27 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.28 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.29 Australia Market
• 11.30 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.31 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.32 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.33 Indonesia Market
• 11.34 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.35 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.36 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate tax structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.6 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
• 12.7 UK Market
• 12.8 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.9 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.11 Germany Market
• 12.12 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.13 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.15 France Market
• 12.16 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.17 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.19 Italy Market
• 12.20 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.21 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.22 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.23 Spain Market
• 12.24 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.25 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.26 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Major companies
• 13.3 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.6 Russia Market
• 13.7 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.8 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.9 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.6 North America Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
• 14.7 USA Market
• 14.8 Summary
• 14.9 Market Overview
  • 14.9.1 Country Information
  • 14.9.2 Market Information
  • 14.9.3 Background Information
  • 14.9.4 Government Initiatives
  • 14.9.5 Regulations
  • 14.9.6 Regulatory Bodies
  • 14.9.7 Major Associations
  • 14.9.8 Taxes Levied
  • 14.9.9 Corporate Tax Structure
  • 14.9.10 Investments
  • 14.9.11 Major Companies
• 14.10 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.11 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.12 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.13 Canada Market
• 14.14 Summary
• 14.15 Market Overview
  • 14.15.1 Country Information
  • 14.15.2 Market Information
  • 14.15.3 Background Information
  • 14.15.4 Government Initiatives
  • 14.15.5 Regulations
  • 14.15.6 Regulatory Bodies
  • 14.15.7 Major Associations
  • 14.15.8 Taxes Levied
  • 14.15.9 Corporate Tax Structure
  • 14.15.10 Investments
  • 14.15.11 Major Companies
• 14.16 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.17 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.18 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Major Companies
• 15.3 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.6 Brazil Market
• 15.7 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.8 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.9 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Major Companies
• 16.3 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Major Companies
• 17.3 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

• 18.1 Company Profiles
• 18.2 Merck & Co., Inc
  • 18.2.1 Company Overview
  • 18.2.2 Products And Services
  • 18.2.3 Business Strategy
  • 18.2.4 Financial Overview
• 18.3 AstraZeneca plc
  • 18.3.1 Company Overview
  • 18.3.2 Products And Services
  • 18.3.3 Business Strategy
  • 18.3.4 Financial Overview
• 18.4 Bristol Myers Squibb Company
  • 18.4.1 Company Overview
  • 18.4.2 Products And Services
  • 18.4.3 Business Strategy
  • 18.4.4 Financial Overview
• 18.5 F. Hoffman-La Roche Ltd
  • 18.5.1 Company Overview
  • 18.5.2 Products And Services
  • 18.5.3 Business Strategy
  • 18.5.4 Financial Overview
• 18.6 Pfizer Inc
  • 18.6.1 Company Overview
  • 18.6.2 Products And Services
  • 18.6.3 Business Strategy
  • 18.6.4 Financial Overview

19 Other Major And Innovative Companies

• 19.1 Eli Lilly and Company
  • 19.1.1 Company Overview
  • 19.1.2 Products And Services
• 19.2 Regeneron Pharmaceuticals Inc.
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
• 19.3 Amgen Inc.
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
• 19.4 Novartis AG
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
• 19.5 Takeda Pharmaceutical Company Limited
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
• 19.6 Janssen Biotech, Inc.
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
• 19.7 Rigel Pharmaceuticals, Inc.
  • 19.7.1 Company Overview
  • 19.7.2 Products And Services
• 19.8 Partner Therapeutics/Merus N.V.
  • 19.8.1 Company Overview
  • 19.8.2 Products And Services
• 19.9 AbbVie Inc.
  • 19.9.1 Company Overview
  • 19.9.2 Products And Services
• 19.10 Nuvation Bio
  • 19.10.1 Company Overview
  • 19.10.2 Products And Services
• 19.11 Iovance Biotherapeutics
  • 19.11.1 Company Overview
  • 19.11.2 Products And Services
• 19.12 Dizal Pharmaceutical
  • 19.12.1 Company Overview
  • 19.12.2 Products And Services
• 19.13 Daiichi Sankyo / AZ
  • 19.13.1 Company Overview
  • 19.13.2 Products And Services
• 19.14 Xcovery Holdings, Inc.
  • 19.14.1 Company Overview
  • 19.14.2 Products And Services
• 19.15 Boehringer Ingelheim
  • 19.15.1 Company Overview
  • 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

• 22.1 Bristol Myers Squibb Expands Oncology Reach WITH $4.8b Mirati Therapeutics Acquisition
• 22.2 Pierre Fabre Acquires Vertical Bio To Advance Novel NSCLC Therapy Pipeline
• 22.3 Bristol Myers Squibb Expands Precision Oncology With $4.1b Turning Point Therapeutics Acquisition

23 Recent Developments In The Non-small Cell Lung Cancer (NSCLC) Market

• 23.1 First-In-Class PD-1/VEGF Bispecific Antibody Wins Approval For Frontline Lung Cancer Treatment
• 23.2 FDA Approves Optune Lua Combination Therapy for Advanced Lung Cancer Patients

24 Opportunities And Strategies

• 24.1 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Countries Offering Most New Opportunities
• 24.2 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Segments Offering Most New Opportunities
• 24.3 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 - Growth Strategies
  • 24.3.1 Market Trend Based Strategies
  • 24.3.2 Competitor Strategies

25 Non-Small Cell Lung Cancer (NSCLC) Market, Conclusions And Recommendations

• 25.1 Conclusions
• 25.2 Recommendations
  • 25.2.1 Product
  • 25.2.2 Place
  • 25.2.3 Price
  • 25.2.4 Promotion
  • 25.2.5 People

26 Appendix

• 26.1 Geographies Covered
• 26.2 Market Data Sources
• 26.3 Research Methodology
• 26.4 Currencies
• 26.5 The Business Research Company
• 26.6 Copyright and Disclaimer